Culotte stenting for coronary bifurcation lesions with 2nd and 3rd generation everolimus-eluting stents: the CELTIC Bifurcation Study
EuroIntervention 2018;14:e318-e324 published online ahead of print May 2018 published online e-edition June 2018. DOI: 10.4244/EIJ-D-18-00346
Simon J. Walsh1*, MD; Colm G. Hanratty1, MD; Stuart Watkins2, MD; Keith G. Oldroyd2, MD; Niall T. Mulvihill3, MD; Mark Hensey3, MD; Alex Chase4, MD; Dave Smith4, MD; Nick Cruden5, MD; James C. Spratt5,6, MD; Darren Mylotte7, MD; Tom Johnson8, MD; Jonathan Hill9, MD; Hafiz M. Hussein10, MB BCh; Kris Bogaerts11, PhD; Marie-Claude Morice12, MD; David P. Foley10, MD
1. Belfast Health & Social Care Trust, Belfast, Northern Ireland, United Kingdom; 2. Golden Jubilee National Hospital, Glasgow, Scotland, United Kingdom; 3. St. Vincent’s Hospital, Dublin, Ireland; 4. Morriston Hospital, Swansea, Wales, United Kingdom
Aims: The aim of this study was to provide contemporary outcome data for patients with de novo coronary disease and Medina 1,1,1 lesions who were treated with a